ScinoPharm Taiwan, Ltd. Stock

Equities

1789

TW0001789006

Pharmaceuticals

End-of-day quote Taiwan S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
28.2 TWD +0.89% Intraday chart for ScinoPharm Taiwan, Ltd. +1.62% +6.82%
Sales 2024 * 2.98B 91.51M Sales 2025 * - Capitalization 22.3B 685M
Net income 2024 * 197M 6.05M Net income 2025 * - EV / Sales 2024 * 7.48 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
108 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 27.41%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.89%
1 week+1.62%
Current month+1.99%
1 month+6.42%
3 months+10.81%
6 months+6.21%
Current year+6.82%
More quotes
1 week
26.45
Extreme 26.45
28.40
1 month
26.00
Extreme 26
29.20
Current year
24.30
Extreme 24.3
29.20
1 year
24.30
Extreme 24.3
35.80
3 years
22.35
Extreme 22.35
35.80
5 years
22.35
Extreme 22.35
40.50
10 years
21.70
Extreme 21.7
73.09
More quotes
Managers TitleAgeSince
Chief Executive Officer - 18-07-31
Director of Finance/CFO - 18-08-19
Chief Tech/Sci/R&D Officer - 20-05-17
Members of the board TitleAgeSince
Director/Board Member - 16-11-09
Director/Board Member - 10-07-04
Chairman 68 10-07-05
More insiders
Date Price Change Volume
24-04-24 28.2 +0.89% 846 894
24-04-24 27.95 -0.18% 999,841
24-04-23 28 +2.00% 1,309,510
24-04-22 27.45 +2.62% 1,061,416
24-04-19 26.75 -3.25% 1,518,938

End-of-day quote Taiwan S.E., April 24, 2024

More quotes
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
28.2 TWD
Average target price
26 TWD
Spread / Average Target
-7.80%
Consensus